Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022

December 19, 2025 updated by: asmaa salama ibrahim, Suez Canal University
Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease. As carcinoid tumors are rare and there are no data supporting stage migration, the aim of this study was to perform comprehensive trends analysis in addition to survival analysis over two decades.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

93481

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

the investigators analyzed the data from cancer registries participating in Surveillance, Epidemiology, and End Results (SEER) software for patients diagnosed with primary GI carcinoid tumors from 2000-2022 using a rate session to calculate the percent change and annual percent change in addition to incidence rates.

Description

Inclusion Criteria:

  • patients with gastrointestinal carcinoid tumors

Exclusion Criteria:

  • patients with unknown age data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The percent change and annual percent change for gastrointestinal carcinoids
Time Frame: 2000-2022
2000-2022
the percent change and annual percent change for gastrointestinal carcinoids across different stage distribution at diagnosis (localized, regional, distant, unknown)
Time Frame: 2000-2022
2000-2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Suez Canal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2000

Primary Completion (Actual)

December 30, 2022

Study Completion (Actual)

December 30, 2022

Study Registration Dates

First Submitted

December 19, 2025

First Submitted That Met QC Criteria

December 19, 2025

First Posted (Actual)

January 5, 2026

Study Record Updates

Last Update Posted (Actual)

January 5, 2026

Last Update Submitted That Met QC Criteria

December 19, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A278

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoid Tumor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe